glp 1 microdose results Microdosing of GLP-1's / Wellness Services / Services THE GLP-1 MICRODOSING PROGRAM

Expanding clinical evidence is likely to increase payer review of GLP-1 drugs across diabetes and weight management programs

Its the early testing edge that has Regeneron excited about Hansohs HS-20094, since the drug has already been studied in over 1k patients, leading Regeneron to claim it has a potentially similar profile to Lillys popular GLP-1/GIP agonist

Safety Profile Well-Tolerated : Semaglutide is generally well-tolerated, with common side effects being gastrointestinal, such as nausea and vomiting, which typically decrease over time

Key Benefits

People want to do the right thing they want to lose weight, they want to stress less, to be more active, to feel better, and to age well